Sangamo Biosciences (SGMO) Misses Q2 EPS by 14c
Get Alerts SGMO Hot Sheet
Price: $0.49 --0%
Financial Fact:
Total operating expenses: 22.03M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Total operating expenses: 22.03M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.38), $0.14 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $5.38 million.
Financial Guidance for 2016 The Company updates guidance as follows:
- Cash and Investments: Sangamo expects that its cash, cash equivalents and marketable securities will be at least $140 million at the end of 2016, inclusive of research funding from existing collaborators but exclusive of funds arising from any additional new collaborations or partnerships, equity financings or other new sources.
- Revenues: Sangamo expects that revenues will be in the range of $12 million to $17 million in 2016, inclusive of research funding from existing collaborations.
- For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c
- Deutsche Bank (DB) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!